Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD 0.02.EBIT: As of FY2025 Q3, the actual value is USD -219.37 K.<h3>Segment Revenue and Operational Metrics</h3><ul><li>Net Income: For the three months ended September 30, 2025, net income was $156,241, compared to $35,034 for the same period in 2024. For the nine months ended September 30, 2025, net income was $239,933, compared to $792,407 for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended September 30, 2025, expenses were $82,467, compared to $203,143 in 2024. For the nine months ended September 30, 2025, expenses were $486,454, compared to $926,412 in 2024.</li><li>Interest Income: Interest earned on cash and investments held in the Trust Account was $187,803 for the three months ended September 30, 2025, and $554,482 for the nine months ended September 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was - $338,888, compared to - $694,222 for the same period in 2024.</li><li>Net Cash (Used in) Provided by Investing Activities: For the nine months ended September 30, 2025, net cash used was - $224,088, compared to $49,200,325 provided in 2024.</li><li>Net Cash Provided by (Used in) Financing Activities: For the nine months ended September 30, 2025, net cash provided was $545,075, compared to - $49,175,380 used in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company intends to use the funds held in the Trust Account to complete a Business Combination, with a focus on identifying a target in Asia (excluding China, Hong Kong, and Macau) that is developing breakthrough technology in life sciences or sustainable technology.</li><li>Non-Core Business: The company has extended the deadline for completing a Business Combination multiple times, with the current extension allowing until March 3, 2026, if further monthly extensions are elected.</li><li>Priority: The company is focused on consummating a Business Combination by the end of the Combination Period to avoid mandatory liquidation of the Trust Account.</li></ul>

VALUENCE MERGER CORP I C/WTS 18/02/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0